5 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
7d
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
4 Reasons to Bet on Small-Cap ETFs Now http://www.zacks.com/stock/news/1063335/4-reasons-to-bet-on-small-cap-etfs-now?cid=CS-ZC-FT-etf_news_and_commentary-1063335 Sep 25, 2020 - Small-cap stocks were hurt badly during the peak of the coronavirus-led lockdowns. Now, the gradual uptick of reopening trade has started to favor the small-cap spectrum.
Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio http://www.zacks.com/stock/news/1068697/why-eli-lilly-lly-is-a-top-dividend-stock-for-your-portfolio?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-1068697 Sep 29, 2020 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
RedHill Gets Nod in Brazil for Coronavirus Study on Opaganib http://www.zacks.com/stock/news/1062512/redhill-gets-nod-in-brazil-for-coronavirus-study-on-opaganib?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-1062512 Sep 23, 2020 - The Brazilian Health Regulatory Agency okays RedHill's (RDHL) to conduct a phase II/III study on opaganib for treating patients with severe COVID-19 infection and pneumonia. Stock up.
Pfizer's (PFE) Xeljanz Gets FDA Approval for 4th Indication http://www.zacks.com/stock/news/1068320/pfizers-pfe-xeljanz-gets-fda-approval-for-4th-indication?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-1068320 Sep 29, 2020 - Pfizer's (PFE) Xeljanz gets approval for children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA).
3 Reasons Growth Investors Will Love Lilly (LLY) http://www.zacks.com/stock/news/1068841/3-reasons-growth-investors-will-love-lilly-lly?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_11_growth-1068841 Sep 29, 2020 - Lilly (LLY) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Pages: 1

Page 1